Generic Drug Market on the Rise as China Pharma’s Candesartan Hypertension Product Passes Tough Consistency Evaluation

China Pharma Holdings, Inc. (NYSE American: CPHI), a leading specialty pharmaceutical company, is delighted to announce the successful approval for its candesartan tablets from the National Medical Products Administration of China. This approval indicates that the quality and efficacy of the generic drug has been verified by a thorough evaluation process. The medication will now be produced by its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.

Generic drugs are an important tool in helping to control costs and ensure public safety in medicine, and the consistency evaluation of generic drugs is essential to ensure their quality and efficacy match that of the innovator drug they are meant to replace. Approved generic drugs are measured according to this principle, so that they can be safely and confidently used in clinical practice and provide equal outcomes to the original.

Candesartan is a powerful angiotensin II receptor antagonist (ARB) used to treat primary hypertension. It comes in the smallest dosage of any sartan drug, 4-16mg once a day, and has the strongest and most stable binding to AT1 receptors. Not only does it help to keep blood pressure levels stable throughout the day, but it can reduce morning spikes and target organ damage from fluctuations, as well as improve outcomes and survival rates for patients with chronic heart failure, along with alleviating symptoms and enhancing exercise capacity.

China is home to an estimated 290 million cardiovascular disease patients, with hypertensive patients making up an astonishing 270 million of that figure. In 2021, the sales of candesartan tablets in public hospitals and retail pharmacies across the country amounted to a staggering RMB226 million (USD$35 million) and RMB173 million (USD$27 million), respectively, according to data from Mi Nei Net.

Ms. Zhilin Li, China Pharma’s Chairman and CEO, shared her enthusiasm for the success of China Pharma’s signature product Candesartan tablets, as it passed the generic-drug-consistency-evaluation from the NMPA. With this achievement, not only will the clinical benefits of its cost-effective alternatives be recognized, but it puts China Pharma in the running to participate in China’s national centralized procurement, providing them a competitive edge in government procurement.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is delivering high-impact treatments to the Chinese population where it’s needed most. With a wide range of products focused on cardiovascular, CNS, infectious, and digestive diseases — all made within the strictest of GMP standards — starting from our HQ in Haikou City, Hainan Province, our comprehensive distribution network reaches major cities and provinces across the country. Use our website to learn more about our cost-efficient business model and how you can access our diverse catalog of life-saving medicines.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from these forward-looking statements. Such risks and uncertainties include, but are not limited to: financial guidance achievability; success of new product development; unexpected changes in demand; increased competition; recession in the Chinese economy; and inadequate levels of research and development.

These forward-looking statements only reflect the date of this press release and the Company is legally bound to update any forward-looking statement to align with actual results or changes in the Company’s expectations, in accordance with applicable law or regulation.

Leave a Comment